Atuação da clínica jurídica Cravinas no enfrentamento às violações de direitos sexuais e reprodutivos durante a pandemia de COVID-19

Objective: to explore the potential actions of intervention by a legal clinic focusing on human rights in the context of a health emergency with severe repercussions for vulnerable women and girls. Methods: the research adopts a case study approach, examining the activities of Cravinas, an extension project at the University of Brasilia (UnB) that operates as a pro bono office specializing in sexual and reproductive rights. The investigation specifically delves into Cravinas\u27 initiatives during the COVID-19 pandemic. Results: the profound health crisis induced by COVID-19 prompted Cravinas to realign its priorities, emphasizing healthcare under open attack by the federal government. The clinic\u27s interventions were centered around providing access to information, delivering health and rights training, and engaging in strategic litigation. These strategies collectively constituted a conscientious and committed effort to defend populations that historically found themselves outside the ambit of public policy priorities. Conclusion: in the face of a crisis, legal clinics possess the potential to propose counter-hegemonic urgencies, offering responses to challenges and providing support for individuals not prioritized in public policies linked to the pandemic. Received: 30/04/23|Review: 08/10/23|Accepted: 31/10/23Objetivo: investigar las posibilidades de actuación de una clínica jurídica en derechos humanos ante una emergencia sanitaria con efectos dramáticos para mujeres y niñas vulnerables. Metodología: estudio de caso del trabajo de Cravinas, proyecto de extensión de la Universidad de Brasilia (UnB) que presta asistencia legal gratuita por los derechos sexuales y reproductivos, durante la pandemia de COVID-19. Resultados: la grave crisis sanitaria generada por el COVID-19 reposicionó las prioridades de Cravinas para poner de relieve la atención sanitaria abiertamente atacada por el gobierno federal. Las acciones de la clínica priorizaron el acceso a la información, la capacitación en salud y derechos y el litigio estratégico, en una constelación de estrategias atentas y comprometidas con la defensa de poblaciones que nunca habían estado en las prioridades de la agenda pública. Conclusión: frente a un escenario de crisis, las clínicas jurídicas pueden ayudar a proponer urgencias contra hegemónicas capaces de responder a los problemas y atender a las personas que están fuera de la agenda prioritaria de las políticas públicas vinculadas a la pandemia. Recepción: 30/04/23|Revisión: 08/10/23|Aceptación: 31/10/23Objetivo: investigar as possibilidades de atuação de uma clínica jurídica em direitos humanos diante de uma emergência sanitária com efeitos dramáticos para mulheres e meninas vulneráveis. Metodologia: estudo de caso da atuação do Cravinas, projeto de extensão da Universidade de Brasília (UnB) que atua como uma clínica jurídica em direitos sexuais e reprodutivos, durante a pandemia de COVID-19. Resultados: a grave crise de saúde gerada pela COVID-19 reposicionou as prioridades do Cravinas para evidenciar cuidados em saúde abertamente atacados pelo governo federal. A atuação da clínica priorizou ações de acesso à informação, de formação em saúde e direitos e de litígio estratégico, em uma constelação de estratégias atenta e engajada na defesa de populações que nunca estiveram nas prioridades da agenda pública. Conclusão: diante de um cenário de crise, as clínicas jurídicas podem ajudar a propor urgências contra-hegemônicas capazes de responder a problemas e a cuidar de pessoas que estão fora da agenda prioritária das políticas públicas ligadas à pandemia. Submissão: 30/04/23|Revisão: 08/10/23|Aprovação: 31/10/2

Associação entre a ooforectomia bilateral precoce e o desenvolvimento do parkinsonismo e Doença de Parkinson em mulheres na pré-menopausa

O parkinsonismo é um distúrbio do sistema nervoso de maior incidência masculina do que feminina, visto que, por mecanismos fisiológicos, o estrogênio possui efeitos neuroprotetores, com funções como aumento da dopamina, um neurotransmissor essencial para o controle das funções motoras. Além disso, previne a formação dos corpúsculos de Lewy e da agregação da α-sinucleína, responsáveis pela progressão da Doença de Parkinson. Por isso, a doença se apresenta diferentemente nas mulheres. A remoção cirúrgica de ambos os ovários em mulheres na pré-menopausa para a prevenção do câncer de ovário parece favorecer o surgimento da doença, tendo em vista a perda da produção do hormônio protetor. Assim, o objetivo do estudo é analisar a associação entre a ooforectomia bilateral precoce e o desenvolvimento de parkinsonismo e Doença de Parkinson em mulheres na pré-menopausa. Trata-se de uma revisão bibliográfica sistemática, do tipo quantitativa, que utilizou as plataformas do PubMed, SciELO e Cochrane Library como bases de dados para seleção dos artigos, todos na língua inglesa. Foram utilizadas literaturas publicadas com recorte temporal de 2017 a 2022. De acordo com as literaturas analisadas, a ooforectomia bilateral precoce em mulheres na pré-menopausa aumenta o risco do desenvolvimento de parkinsonismo. Desse modo, a diminuição dos procedimentos cirúrgicos profiláticos para câncer de ovário nas pacientes com risco médio de malignidade reduziria o risco dessa condição

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Direitos sexuais e reprodutivos das mulheres

Camila Giugliani, Daniela Knauth e integrantes do Projeto Cravinas (Brasília) abordam questões sobre o direito de autonomia sobre o corpo, a liberdade de escolher sua orientação sexual e sua vida reprodutiva. Tratam de como esses direitos foram adquiridos e salientam sobre a necessidade de continuar lutando por direitos conquistados, mas que não estão garantidos. O módulo, com dez vídeos, faz parte do Curso: “Feminimos: Algumas Verdades Inconvenientes" disponível na Plataforma Lúmina/UFRGS e pode ser acessado pelo link: https://lumina.ufrgs.br/course/view.php?id=100#section-2Não é possível instalar um arquivo de vídeo. Apenas transfira-o para seu computador e abra como um arquivo comum. Arquivos de vídeo não podem ser editados, mas podem ser visualizados em players como o VLC Media Player (que é gratuito), o Windows Media Player ou o QuickTime. Os formatos mais comuns de vídeo serão executados normalmente por estes players (avi, mpeg e mp4).VídeoApesar de haver uma ordem sugerida para acompanhar os vídeos, eles são independentes e têm conteúdos autocontidos

Characterisation of microbial attack on archaeological bone

As part of an EU funded project to investigate the factors influencing bone preservation in the archaeological record, more than 250 bones from 41 archaeological sites in five countries spanning four climatic regions were studied for diagenetic alteration. Sites were selected to cover a range of environmental conditions and archaeological contexts. Microscopic and physical (mercury intrusion porosimetry) analyses of these bones revealed that the majority (68%) had suffered microbial attack. Furthermore, significant differences were found between animal and human bone in both the state of preservation and the type of microbial attack present. These differences in preservation might result from differences in early taphonomy of the bones. © 2003 Elsevier Science Ltd. All rights reserved

NEOTROPICAL ALIEN MAMMALS: a data set of occurrence and abundance of alien mammals in the Neotropics

Biological invasion is one of the main threats to native biodiversity. For a species to become invasive, it must be voluntarily or involuntarily introduced by humans into a nonnative habitat. Mammals were among first taxa to be introduced worldwide for game, meat, and labor, yet the number of species introduced in the Neotropics remains unknown. In this data set, we make available occurrence and abundance data on mammal species that (1) transposed a geographical barrier and (2) were voluntarily or involuntarily introduced by humans into the Neotropics. Our data set is composed of 73,738 historical and current georeferenced records on alien mammal species of which around 96% correspond to occurrence data on 77 species belonging to eight orders and 26 families. Data cover 26 continental countries in the Neotropics, ranging from Mexico and its frontier regions (southern Florida and coastal-central Florida in the southeast United States) to Argentina, Paraguay, Chile, and Uruguay, and the 13 countries of Caribbean islands. Our data set also includes neotropical species (e.g., Callithrix sp., Myocastor coypus, Nasua nasua) considered alien in particular areas of Neotropics. The most numerous species in terms of records are from Bos sp. (n = 37,782), Sus scrofa (n = 6,730), and Canis familiaris (n = 10,084); 17 species were represented by only one record (e.g., Syncerus caffer, Cervus timorensis, Cervus unicolor, Canis latrans). Primates have the highest number of species in the data set (n = 20 species), partly because of uncertainties regarding taxonomic identification of the genera Callithrix, which includes the species Callithrix aurita, Callithrix flaviceps, Callithrix geoffroyi, Callithrix jacchus, Callithrix kuhlii, Callithrix penicillata, and their hybrids. This unique data set will be a valuable source of information on invasion risk assessments, biodiversity redistribution and conservation-related research. There are no copyright restrictions. Please cite this data paper when using the data in publications. We also request that researchers and teachers inform us on how they are using the data